A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Main Article Content

Andreas Wollenberg
Michael D Howell
Emma Guttman-Yassky
Jonathan I Silverberg
Claire Birrell
Christopher Kell
Koustubh Ranade
Michelle Dawson
Rene van der Merwe


tralokinumab, atopic dermatitis, biologic therapy


Abstract not available.


Disclosures: Study sponsored by LEO Pharma


Copyright 2018 SKIN

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>